Nail involvment in psoriatic arthritis.
Data nadesłania: 10-04-2017
Data ostatniej rewizji: 30-05-2017
Data akceptacji: 01-06-2017
Data publikacji online: 18-07-2017
Data publikacji: 30-06-2017
Reumatologia 2017;55(3):131-135
Nail psoriasis is considered a significant psychological and social problem causing functional impairment in affected patients. Nail changes hamper their daily and occupational activities and contribute to a worse quality of life. Almost 50% of patients with psoriasis vulgaris and up to 80% of patients with psoriatic arthritis are afflicted with nail lesions. The important correlation between psoriatic arthritis and nail changes is well established – the presence of the latter is a strong predictor of the development of arthritis. There is a broad spectrum of nail dystrophies associated with psoriasis, ranging from the common pitting, subungual hyperkeratosis and loosening of the nail plate to less frequent discolouration and splinter haemorrhages. Some of these symptoms are also observed in other nail diseases, and further diagnostics should be performed. The assessment tools NAPSI (Nail Psoriasis Severity Index), mNAPSI (Modified Nail Psoriasis Severity Index), and PNSS (Psoriasis Nail Severity Score) are most commonly used to grade the severity of nail involvement in psoriasis and enable the evaluation of therapy effectiveness. The treatment of nail psoriasis is a major clinical challenge. It should be adjusted to the extent of dermal, articular and ungual lesions. Systemic therapies of psoriasis, especially biological agents, are most likely to be effective in treating nail psoriasis. However, as their use is limited in scope and safety, topical therapy remains a mainstay, and the combination of corticosteroids and vitamin D3 analogues is considered to be most helpful.
Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anathomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 1-27.
Wolska H. Nail psoriasis. Przegl Dermatol 2010; 97: 243-253.
de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996; 193: 300-303.
Crowley J, Weinberg J, Wu J, et al. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol 2015; 151: 87-94.
Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009; 23 Suppl 1: 15-21.
Armesto S, Esteve A, Coto-Segura P, et al. Nail psoriasis in individuals with psoriasis vulgaris:a study of 661 patients. Actas Dermosifiliogr 2011; 102: 365-372.
Raposo I, Torres T. Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermosifiliogr 2015; 106: 452-457.
Braun-Falco O, Plewig G, Wolff HH. Dermatology 2000; 1073-1078.
Achten G, Parent D. The normal and pathologic nail. Int J Dermatol 1983; 22: 556-565.
Grover C, Reddy BS, Uma Chaturvedi K. Diagnosis of nail psoriasis: importance of biopsy and histopathology. Br J Dermatol 2005; 153: 1153-1158.
Zaias N. The nail in health and disease. 2nd ed. Appleton & Lange, Norwalk 1990.
Fawcett RS, Linford S, Stulberg DL. Nail abnormalities: clues to systemic disease. Am Fam Physician 2004; 69: 1417-1424.
Scher RK, Daniel CR. Nails: therapy, diagnosis, surgery. W.B. Saunders Company, Philadelphia 2003.
Schons KR, Knob CF, Murussi N, et al. Nail psoriasis: a review of the literature. An Bras Dermatol 2014; 89: 312-317.
Tan ES, Chong WS, Tey HL. Nail psoriasis: a review. Am J Clin Dermatol 2012; 13: 375-388.
Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg 2003; 7: 317-321.
Lavaroni G, Kokelj F, Pauluzzi P, et al. The nail in psoriatic arthritis. Acta Derm Venereol Suppl (Stockh) 1994; 186: 113.
Sandre MK, Rohekar S. Psoriatic arthritis and nail changes: exploring the relationship. Semin Arthritis Rheum 2014; 44: 162-169.
Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 Suppl 2: 31-5.
Langenbruch A, Radtke MA, Krensel M, et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol 2014; 171: 1123-1128.
Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis – a high-resolution MRI and histological study. Rheumatology (Oxford) 2007; 46: 253-256.
Aydin SZ, Castillo-Gallego C, Ash ZR, et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology 2012; 225: 231-235.
Sandre MK, Rohekar S, Guenther L. Psoriatic Nail changes are associated with clinical outcomes in psoriatic arthritis. J Cutan Med Surg 2015; 19: 367-376.
Schons KR, Beber AA, Beck Mde O, et al. Nail involvement in adult patients with plaque-type psoriasis: prevalence and clinical features. Bras Dermatol 2015; 90: 314-319.
Rigopoulos D, Gregoriou S, Daniel CR III, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology 2009; 218: 338-341.
Rigopoulos D, Ioannides D, Prastitis N, et al. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 2002; 82: 140.
Gümüşel M, OzdemirM, Mevlitoğlu I, et al. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 2011; 25: 1080-1084.
Brazzelli V, Martinoli S, Prestinari F, et al. An impressive therapeutic result of nail psoriasis to acitretin. J Eur Acad Dermatol Venereol 2004; 18: 229-230.
Baran R. Retinoids and the nails. J Dermatol Treat 1990; 1: 151-154.
Ortonne JP, Paul C, Berardesca E, et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol 2013; 168: 1080-1087.
Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor-antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60: 976-986.
Reich K, Ortonne JP, Kerkmann U, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology 2010; 221: 172-178.
Igarashi A, Kato T, Kato M, et al. Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39: 242-252.
Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 2011; 147: 429-436.
Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58: 224-231.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top